Brief: Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism
14/10/2026 22:02
BRIEF-Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism Oct 14 (Reuters) - Rezolute, Inc. RZLT.O:
REZOLUTE ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 3 UPLIFT STUDY OF ERSODETUG IN TUMOR HYPERINSULINISM
REZOLUTE - COMPLETES ENROLLMENT IN PHASE 3 UPLIFT STUDY; TOPLINE RESULTS EXPECTED MID-DECEMBER 2026
REZOLUTE - PRIMARY ENDPOINT IS 50% REDUCTION IN GLUCOSE INFUSION RATE WITHIN 8 WEEKS
REZOLUTE: PLANS TO CONTINUE EXPANDED ACCESS PROGRAM FOR COMPASSIONATE USE OF ERSODETUG IN TUMOR HI
Source text: ID:nGNX50f0N7
Further company coverage: RZLT.O
((((Reuters.Briefs@thomsonreuters.com;));))